Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Drops By 15.4%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIBGet Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,400 shares, a drop of 15.4% from the January 15th total of 5,200 shares. Based on an average daily trading volume, of 11,900 shares, the short-interest ratio is currently 0.4 days.

ProShares Ultra Nasdaq Biotechnology Price Performance

Shares of NASDAQ:BIB traded down $0.18 during trading hours on Monday, hitting $55.17. The stock had a trading volume of 9,601 shares, compared to its average volume of 10,563. The stock’s fifty day simple moving average is $53.40 and its 200 day simple moving average is $59.49. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $47.19 and a 1-year high of $69.56.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were paid a dividend of $0.3964 per share. This is a boost from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Crowley Wealth Management Inc. acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at $51,000. Tower Research Capital LLC TRC raised its position in ProShares Ultra Nasdaq Biotechnology by 31.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund’s stock worth $270,000 after acquiring an additional 1,266 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in ProShares Ultra Nasdaq Biotechnology by 8.4% in the 3rd quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock valued at $306,000 after acquiring an additional 374 shares during the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Featured Articles

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.